Search clinical trials for: Placebo Asenapine

Total 53509 results

Organon and Co

Completed

6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)

Schizophrenia
Organon and Co

Completed

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)

Schizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
Organon and Co

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

Schizophrenia | Bipolar I Disorder
Organon and Co

Completed

To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

Schizophrenia
Lori Davis, MD
Merck Sharp & Dohme LLC; Forest Laboratories

Completed

An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Posttraumatic Stress Disorder

United States
Duke University
Merck Sharp & Dohme LLC

Completed

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

Major Depressive Disorder Without Psychotic Features

United States
Organon and Co

Completed

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Bipolar Disorder, Pediatric
Duke University
Merck Sharp & Dohme LLC

Completed

Once-Daily Asenapine for Schizophrenia

Schizophrenia

United States
Forest Laboratories

Completed

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

Bipolar 1 Disorder

United States, Bulgaria, Croatia, India, Philippines, Romania, Russian Federation, Serbia, Turkey, Ukraine
Organon and Co

Completed

A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

Schizophrenia | Schizoaffective Disorder
Noven Pharmaceuticals, Inc.

Completed

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. (HP-3070)

Schizophrenia

United States
Organon and Co

Completed

An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)

Psychosis
Amneal Pharmaceuticals, LLC
Accutest Research Laboratories (I) Pvt. Ltd.

Completed

Bioequivalence Fasting Study in Patients

Schizophrenia

India
Organon and Co

Completed

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

Schizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

Bipolar I Disorder

United States
Organon and Co

Completed

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

Schizophrenia
Organon and Co
Meiji Seika Pharma Co., Ltd.

Completed

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Schizophrenia
Unity Health Toronto
Schering-Plough

Completed

Treating Acutely Agitated Patients With Asenapine Sublingual Tablets

Agitation

United States
Organon and Co

Completed

40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)

Bipolar Disorder
University of Cincinnati
Merck Sharp & Dohme LLC; University of Louisville

Terminated

Asenapine for Bipolar Depression

Bipolar Depression

United States
Organon and Co

Completed

12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

Bipolar Disorder
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

Schizophrenia

United States
Organon and Co

Completed

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

Schizophrenia
Organon and Co

Completed

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

Schizophrenia
Organon and Co

Completed

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Bipolar 1 Disorder
Centre de Recherche de l'Institut Universitaire...

Unknown

Investigator Initiated Study - Asenapine Early Psychosis

Disorders | Schizophrenia and Disorders With Psychotic Features

Canada
Organon and Co

Completed

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

Schizophrenia
Organon and Co

Completed

Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

Schizophrenia
Organon and Co

Completed

Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

Psychosis
University Hospitals Cleveland Medical Center
Case Western Reserve University

Completed

Asenapine in the Treatment of Older Adults With Bipolar Disorder

Bipolar Disorder

United States
Sun Pharmaceutical Industries Limited
bioRASI, LLC

Completed

Bio-equivalence Study Between SAPHRIS and Asenapine (ASN)

Schizophrenia | Bipolar Disorder

United States
Organon and Co
Pfizer

Completed

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

Bipolar Disorder
Organon and Co

Completed

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Schizophrenia
Organon and Co

Completed

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Schizophrenia
Organon and Co

Completed

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) (ACTAMESA)

Schizophrenia | Schizoaffective Disorder
University of California, Irvine
Merck Sharp & Dohme LLC

Suspended

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

Stuttering

United States
Organon and Co

Completed

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

Schizophrenia | Schizoaffective Disorder
Organon and Co

Completed

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Schizophrenia
Organon and Co

Completed

Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

Schizophrenia
Organon and Co
Pfizer

Completed

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

Bipolar Disorder
Organon and Co

Completed

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898) (ADDRESS-98)

Bipolar Disorder
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

United States, France, Austria, Germany
Organon and Co
Pfizer

Completed

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

Bipolar Disorder
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Organon and Co
Pfizer

Completed

9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

Bipolar Disorder
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong

3

Subscribe